



Medication Request Form (MRF) for Healthy Indiana Plan (HIP) and Hoosier Healthwise (HHW)

FAX TO: (858) 790-7100

c/o MedImpact Healthcare Systems, Inc.

Attn: Prior Authorization Department

10181 Scripps Gateway Court, San Diego, CA 92131 - Phone: 1-800-788-2949

Instructions:

This form is to be used by participating providers to obtain coverage for non-preferred formulations of buprenorphine/naloxone. Please complete this form and fax it to MedImpact Healthcare Systems, Inc. at (858) 790-7100. If you have any questions regarding this process, please contact MedImpact's Customer Service at (800) 788-2949.

Member/Provider Information:

|                                           |                                                          |
|-------------------------------------------|----------------------------------------------------------|
| MDwise Member's Name:                     | Provider's Name:                                         |
| MDwise Member's ID #:                     | Provider's Specialty:                                    |
| MDwise Member's DOB (mm-dd-yy):           | Provider's DEA #:   Provider's NPI #:                    |
| Pharmacy used by MDwise Member:           | Provider's Telephone Number/Contact Name (xxx-xxx-xxxx): |
| Pharmacy Telephone Number (xxx-xxx-xxxx): | Provider's Fax Number (xxx-xxx-xxxx):                    |

Clinical Information:

|                                        |                     |
|----------------------------------------|---------------------|
| Requested Drug:                        | Quantity Requested: |
| Strength and Dosage Regimen Requested: | Date Requested:     |

**Documentation of Medical Necessity:**

Did the patient have a hypersensitivity reaction to an inactive ingredient in generic buprenorphine/naloxone SL tablets (hypersensitivity reaction must be documented in submitted chart notes)?  
 Yes     No    (Note: MedWatch form not required, but chart notes must be submitted.)

**OR**

Did the patient fail at least 28 days of treatment with generic buprenorphine/naloxone SL tablets in the previous 120 days due to therapeutic failure or adverse outcome that could not be addressed with dose adjustment?  
 Yes     No

*Prior authorization is contingent upon your submission to the FDA of a completed MedWatch form which describes the therapeutic failure or adverse outcome(s) experienced by the patient with generic buprenorphine/naloxone SL tablets.*

Is a copy of the MedWatch form submitted to the FDA attached to this request for prior authorization?  
 Yes     No

*MedWatch forms can be downloaded at the following address:*  
<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf>

Please attach additional information which may indicate why the **non-preferred** medication is being requested for this patient.